Abstract
Lipid metabolism disorders (dyslipidemias) are considered as the most frequent disease among all metabolic diseases. Dyslipidemias are divided into three groups: hypercholesterolemia, hypertriglyceridemia and combined (mixed) dyslipidemia by European Atherosclerosis Society (1992).
Dyslipidemia treatment should be specified for everybody according his (her) characteristics, i.e. individualized or tailored treatment. Today we make a choice of lipid modifying drugs according to their effects and the type of lipid disorder.
The main aim of lipid disorder treatment is to reduce the total cardiovascular risk. Lowering of LDL cholesterol to the recommended level by total cardiovascular risk represents the immediate primary aim of dyslipidemia therapy.
The secondary aim should be the treatment of high triglycerides or atherogenic dyslipidemia if they are expressed. New biological therapy of dyslipidemia, which is now in the clinical experiment, should contribute to the more individualized therapy, better lipid metabolism control and then to better reduction of cardiovascular morbidity and mortality.